Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice

The development of a safe and effective vaccine to protect against COVID-19 is a global priority due to the current high SARS-CoV-2 infection rate. Currently, there are over 160 SARS-CoV-2 vaccine candidates at the clinical or pre-clinical stages of development. Of these, there are only three whole-...

Descripción completa

Detalles Bibliográficos
Autores principales: Sundaram, Appavu K., Ewing, Daniel, Liang, Zhaodong, Jani, Vihasi, Cheng, Ying, Sun, Peifang, Raviprakash, Kanakatte, Wu, Shuenn-Jue, Petrovsky, Nikolai, Defang, Gabriel, Williams, Maya, Porter, Kevin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160882/
https://www.ncbi.nlm.nih.gov/pubmed/34069575
http://dx.doi.org/10.3390/pathogens10050626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160882/
https://www.ncbi.nlm.nih.gov/pubmed/34069575
http://dx.doi.org/10.3390/pathogens10050626

Ejemplares similares